Author

Lazarus JV

December 1, 2021
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
Summary Background & aims Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD is largely absent on national and global health agendas. Methods We collected data from 102 countries, accounting for […]

Read More
January 19, 2021
Progress towards hepatitis C virus elimination in high-income countries: An updated analysis
Summary Background & aims Elimination of HCV by 2030, as defined by the World Health Organization (WHO), is attainable with the availability of highly efficacious therapies. This study reports progress made in the timing of HCV elimination in 45 high-income countries between 2017 and 2019. Methods Disease progression models of HCV infection for each country […]

Read More
July 28, 2020
The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data
Summary Background New hepatitis C virus (HCV) treatments spurred the World Health Organization (WHO) in 2016 to adopt a strategy to eliminate HCV as a public health threat by 2030. To achieve this, key policies must be implemented. In the absence of monitoring mechanisms, this study aims to assess the extent of policy implementation from […]

Read More
July 27, 2020
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?
Summary Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C? In 2019, a Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viral hepatitis reported on the status of 11 viral hepatitis policy indicators in 66 countries and territories with the heaviest burden by global region. […]

Read More
September 3, 2018
The hepatitis B epidemic and the urgent need for cure preparedness
Summary More than 250 million people worldwide are chronically infected with the hepatitis B virus (HBV). In this Comment, members of the International Coalition to Eliminate HBV appraise the current policy environment and the need for appropriate cure research and preparedness to complement the WHO global elimination strategy, the HBV vaccine and the well- tolerated […]

Read More
July 9, 2018
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations
Summary The introduction of efficacious new hepatitis C virus (HCV) treatments galvanized the World Health Organization to define ambitious targets for eliminating HCV as a public health threat by 2030. Formidable obstacles to reaching this goal can best be overcome through a micro-elimination approach, which entails pursuing elimination goals in discrete populations through multi-stakeholder initiatives […]

Read More
June 8, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Summary Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease […]

Read More
March 6, 2018
Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe
Summary Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically infected with a wide range of variation in prevalence across European Union countries. Although HCV continues to spread as a largely “silent pandemic,” its elimination is made possible through the availability […]

Read More
June 30, 2016
Urgent action to fight hepatitis C in people who inject drugs in Europe
Summary Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and liver cancer, is curable in most people. Injecting drug use currently accounts for 80 % of new HCV infections with a known transmission route in the European Union (EU). HCV has generally received little attention from the public or policymakers in […]

Read More

Author

Lazarus JV

The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

Progress towards hepatitis C virus elimination in high-income countries: An updated analysis

The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data

Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?

The hepatitis B epidemic and the urgent need for cure preparedness

The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe

Urgent action to fight hepatitis C in people who inject drugs in Europe

Useful Links, CDAF

Useful Links, Polaris

Latest News